HPN-01 / Hepanova - LARVOL DELTA

PHARMACOLOGICAL TARGETING OF IKKΑ FOR RESOLUTION OF STEATOSIS, INFLAMMATION, AND FIBROSIS: A MECHANISTIC DISTINCT DEVELOPMENT OF HPN-01 FOR MASH (AASLD 2025) - "HPN-01 is currently under evaluation in a U.S. Phase I clinical trial in healthy volunteers. Preclinical toxicology and initial clinical data indicate a favorable safety profile. Collectively, these findings position HPN-01 as a mechanistically distinct, first-in-class therapeutic candidate capable of addressing the multifaceted pathobiology of MASH and preventing HCC development."

Fibrosis • Genetic Disorders • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Obesity • Solid Tumor • AFP